ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,460.48
      -0.41%
      US Tech 100
      19,181.60
      -0.43%
      Dow Jones
      39,118.86
      -0.12%
      Brent Oil
      84.85
      0.00%
      Bitcoin
      61,436.11
      0.89%
      Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ

      6. Verve Therapeutics Inc (VERV) Quote

      Verve Therapeutics Inc

      Verve Therapeutics Inc (VERV)

      Verbund Ag
      Verbund Ag
      Verbund Ag
      Verbund Ag
      0.00
      0.00
      (0.00%)
      Closed June 30 4:00PM
      Delayed by 15 minutes
      0.00
      0.00
      (0.00%)
      After Hours: -
      Delayed by 15 minutes

      Professional-Grade Tools, for Individual Investors.

      Premium

      Key stats and details

      Current Price
      -
      Bid
      -
      Ask
      -
      Volume
      -
      0.00 Day's Range 0.00
      4.585 52 Week Range 21.04
      Market Cap
      417.309M
      Previous Close
      -
      Open
      -
      Last Trade
      Last Trade Time
      Financial Volume
      -
      VWAP
      -
      Average Volume (3m)
      1,327,879
      Shares Outstanding
      83,965,493
      Dividend Yield
      -
      PE Ratio
      -2.09
      Earnings Per Share (EPS)
      -2.38
      Revenue
      11.76M
      Net Profit
      -200.07M

      About Verve Therapeutics Inc

      Verve Therapeutics Inc is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company's initial two programs target PCSK9 and ANGPTL3, genes that have been extensively... Verve Therapeutics Inc is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company's initial two programs target PCSK9 and ANGPTL3, genes that have been extensively validated as targets for lowering blood lipids such as low-density lipoprotein cholesterol, a root cause of cardiovascular disease. The company views its operations as and manages its business in one operating segment operating exclusively in the United States. Show more

      Sector
      Pharmaceutical Preparations
      Industry
      Pharmaceutical Preparations
      Website
      www.vervetx.com
      Headquarters
      Wilmington, Delaware, USA
      Founded
      1970
      Verve Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker VERV. The last closing price for Verve Therapeutics was -. Over the last year, Verve Therapeutics shares have traded in a share price range of $ 4.585 to $ 21.04.

      Verve Therapeutics currently has 83,965,493 shares outstanding. The market capitalization of Verve Therapeutics is $417.31 million. Verve Therapeutics has a price to earnings ratio (PE ratio) of -2.09.

      VERV Latest News

      More News

      Verve Therapeutics Announces Appointment of Nia Tatsis, Ph.D., and Jodie Morrison to its Board of Directors

      BOSTON, June 28, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene...

      June 28 2024
      GlobeNewswire Inc.

      Form 8-K - Current report

      June 07 2024
      Edgar (US Regulatory)

      Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

      BOSTON, May 31, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene...

      May 31 2024
      GlobeNewswire Inc.

      Form 8-K - Current report

      May 31 2024
      Edgar (US Regulatory)

      Verve Therapeutics Announces Leadership Update

      Troy Lister, Ph.D., to be promoted to chief scientific officer Andrew Bellinger, M.D., Ph.D., will depart the Company and serve in an advisory capacity BOSTON, May 31, 2024 (GLOBE NEWSWIRE...

      May 31 2024
      GlobeNewswire Inc.

      Verve Therapeutics to Participate in Upcoming Investor Conferences

      BOSTON, May 30, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene...

      May 30 2024
      GlobeNewswire Inc.

      Form 10-Q - Quarterly report [Sections 13 or 15(d)]

      May 08 2024
      Edgar (US Regulatory)

      Form 8-K - Current report

      May 08 2024
      Edgar (US Regulatory)

      Verve Therapeutics Announces Pipeline Progress and Reports First Quarter 2024 Financial Results

      First patient dosed in Heart-2 Phase 1b clinical trial of VERVE-102 VERVE-201 clinical trial initiation on track for the second half of 2024 Received first milestone payment from Eli Lilly for...

      May 08 2024
      GlobeNewswire Inc.

      Verve Therapeutics Announces Dosing of First Patient in Heart-2 Phase 1b Clinical Trial Evaluating VERVE-102

      VERVE-102 is an investigational in vivo base editing medicine designed to permanently inactivate the PCSK9 gene in the liver to durably reduce blood low-density lipoprotein cholesterol Heart-2...

      May 07 2024
      GlobeNewswire Inc.
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      1005.175.494.58517805555.18261573CS
      4005.155.794.58513718355.25912178CS
      12008.538.774.58513278796.01283055CS
      260014.619.344.58512809019.51057163CS
      520018.9221.044.585121489611.21444595CS
      1560041.96784.58589375320.36755142CS
      2600030784.58589363920.50168307CS

      Market Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      ASNSActelis Networks Inc
      $ 2.4638
      (66.47%)
      		68.83M
      COSMCosmos Health Inc
      $ 1.06
      (56.11%)
      		79.47M
      LUCYInnovative Eyewear Inc
      $ 0.507001
      (53.64%)
      		356.92M
      NNENano Nuclear Energy Inc
      $ 22.7052
      (39.98%)
      		8.73M
      NBSTWNewbury Street Acquisition Corporation
      $ 0.0613
      (39.32%)
      		19.62k
      CINGCingulate Inc
      $ 0.315
      (-46.06%)
      		2.36M
      ACCDAccolade Inc
      $ 3.53
      (-44.76%)
      		14.63M
      BTOGBit Origin Ltd
      $ 2.95
      (-44.55%)
      		3.3M
      NXLNexalin Technologies Inc
      $ 1.695
      (-42.74%)
      		4.31M
      APVOAptevo Therapeutics Inc
      $ 0.309899
      (-39.81%)
      		2.37M
      LUCYInnovative Eyewear Inc
      $ 0.507001
      (53.64%)
      		356.92M
      NVDANVIDIA Corporation
      $ 124.3812
      (0.32%)
      		248.1M
      FFIEFaraday Future Intelligent Electric Inc
      $ 0.513
      (-14.50%)
      		189.18M
      SQQQProShares UltraPro Short QQQ
      $ 8.20
      (0.86%)
      		142.65M
      TSLATesla Inc
      $ 196.72
      (-0.35%)
      		82.53M

      VERV Discussion

      View Posts
      Monksdream Monksdream 2 days ago
      VERV new 52 week low
      👍️0
      Monksdream Monksdream 3 days ago
      VERV new 52 week low
      👍️0
      Monksdream Monksdream 4 weeks ago
      VERV more new lows up ahead
      👍️0
      Monksdream Monksdream 1 month ago
      VERV new 52 week low
      👍️0
      Monksdream Monksdream 2 months ago
      VERV new 52 week low
      👍️0
      Monksdream Monksdream 2 months ago
      VERV new 52 week low
      👍️0
      Monksdream Monksdream 2 months ago
      VERV new 52 week low
      👍️0
      Monksdream Monksdream 2 months ago
      VERV new 52 lo
      👍️0
      Firestorm22 Firestorm22 3 months ago
      uh oh
      👍️0
      Monksdream Monksdream 3 months ago
      VERV over $10
      👍️0
      fink fink 5 months ago
      Looking for an entry now
      👍️0
      Terpi Terpi 7 months ago
      Could see another nice move here is the 50 day holds into close.
      👍️0
      Monksdream Monksdream 8 months ago
      VERV morning rally
      👍️0
      TheFinalCD TheFinalCD 1 year ago
      https://cathiesark.com/
      👍️0
      crudeoil24 crudeoil24 2 years ago
      VERV IS A GREAT $$$$$ OPPORTUNITY.
      👍️0
      crudeoil24 crudeoil24 2 years ago
      Verve Therapeutics started at outperform with $48 stock price target at BMO Capital
      👍️0
      crudeoil24 crudeoil24 2 years ago
      Verve Therapeutics, Inc. is a genetic medicines company, developing an approach to the care of cardiovascular disease (CVD) transforming treatment from chronic management to single-course gene editing medicines. The Company’s initial two programs target PCSK9 and ANGPTL3, respectively, genes that regulate levels of blood lipids. Its lead product candidate, VERVE-101, is designed to permanently turn off the PCSK9 gene in the liver. Reduction of PCSK9 protein in the blood improves the ability of the liver to clear LDL-C from the blood. VERVE-101 utilizes LNP-mediated delivery to target the liver and base editing technology to make a single base change at a specific site in the PCSK9 gene in order to disrupt PCSK9 protein production. It is advancing VERVE-101 initially for the treatment of heterozygous familial hypercholesterolemia. Its second program is designed to permanently turn off the ANGPTL3 gene in the liver. ANGPTL3 is a key regulator of cholesterol and triglyceride metabolism.
      👍️0

      Your Recent History

      NASDAQ
      VERV
      Verve Therapeutics
      Delayed Upgrade Clock